These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32229581)

  • 1. Antidopaminergic treatment is associated with reduced chorea and irritability but impaired cognition in Huntington's disease (Enroll-HD).
    Harris KL; Kuan WL; Mason SL; Barker RA
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):622-630. PubMed ID: 32229581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO; Philbin M; Carroll B
    Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
    [No Abstract]   [Full Text] [Related]  

  • 3. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
    Verhagen Metman L; Morris MJ; Farmer C; Gillespie M; Mosby K; Wuu J; Chase TN
    Neurology; 2002 Sep; 59(5):694-9. PubMed ID: 12221159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Neuropsychiatry of Huntington Disease-Like 2: A Comparison with Huntington's Disease.
    Ferreira-Correia A; Krause A; Anderson DG
    J Huntingtons Dis; 2020; 9(4):325-334. PubMed ID: 33044188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic approaches to the treatment of Huntington's disease.
    Venuto CS; McGarry A; Ma Q; Kieburtz K
    Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Olanzapine improves chorea in patients with Huntington's disease].
    Jiménez-Jiménez FJ; de Toledo M; Puertas I; Barón M; Zurdo M; Barcenilla B
    Rev Neurol; 2002 Sep 16-30; 35(6):524-5. PubMed ID: 12389168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease.
    Tedroff J; Waters S; Barker RA; Roos R; Squitieri F;
    J Huntingtons Dis; 2015; 4(2):131-40. PubMed ID: 26397894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early-Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease.
    Julayanont P; Heilman KM; McFarland NR
    Mov Disord; 2020 May; 35(5):781-788. PubMed ID: 31922295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic interventions for symptomatic treatment in Huntington's disease.
    Mestre T; Ferreira J; Coelho MM; Rosa M; Sampaio C
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006456. PubMed ID: 19588393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.
    Gibson JS; Claassen DO
    Expert Opin Pharmacother; 2021 Jun; 22(8):1015-1024. PubMed ID: 33550875
    [No Abstract]   [Full Text] [Related]  

  • 11. Survey of the Huntington's Disease Patient and Caregiver Community Reveals Most Impactful Symptoms and Treatment Needs.
    Simpson JA; Lovecky D; Kogan J; Vetter LA; Yohrling GJ
    J Huntingtons Dis; 2016 Dec; 5(4):395-403. PubMed ID: 27983566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.
    Reilmann R; Rouzade-Dominguez ML; Saft C; Süssmuth SD; Priller J; Rosser A; Rickards H; Schöls L; Pezous N; Gasparini F; Johns D; Landwehrmeyer GB; Gomez-Mancilla B
    Mov Disord; 2015 Mar; 30(3):427-31. PubMed ID: 25689146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the management of Huntington's disease.
    Devadiga SJ; Bharate SS
    Bioorg Chem; 2022 Mar; 120():105642. PubMed ID: 35121553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.
    Huntington Study Group
    Neurology; 2003 Dec; 61(11):1551-6. PubMed ID: 14663041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrabenazine: for chorea associated with Huntington's disease.
    Scott LJ
    CNS Drugs; 2011 Dec; 25(12):1073-85. PubMed ID: 22133328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
    Gamez J; Calopa M; Muñoz E; Ferré A; Huertas O; McAllister K; Reig N; Scart-Grès C; Insa R; Kulisevsky J
    Br J Clin Pharmacol; 2023 May; 89(5):1656-1664. PubMed ID: 36494329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.
    Lundin A; Dietrichs E; Haghighi S; Göller ML; Heiberg A; Loutfi G; Widner H; Wiktorin K; Wiklund L; Svenningsson A; Sonesson C; Waters N; Waters S; Tedroff J
    Clin Neuropharmacol; 2010; 33(5):260-4. PubMed ID: 20616707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of Acanthocytosis in Huntington's Disease-like 2: A Prospective Comparison with Huntington's Disease.
    Anderson DG; Carmona S; Naidoo K; Coetzer TL; Carr J; Rudnicki DD; Walker RH; Margolis RL; Krause A
    Tremor Other Hyperkinet Mov (N Y); 2017; 7():512. PubMed ID: 29226019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.
    Gonzalez V; Cif L; Biolsi B; Garcia-Ptacek S; Seychelles A; Sanrey E; Descours I; Coubes C; de Moura AM; Corlobe A; James S; Roujeau T; Coubes P
    J Neurosurg; 2014 Jul; 121(1):114-22. PubMed ID: 24702329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.
    Heo YA; Scott LJ
    Drugs; 2017 Nov; 77(17):1857-1864. PubMed ID: 29080203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.